Clinical trial · Observational
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
Single-cell Sequencing and Establishment of Cell Lines, Organoids, and Transplanted Tumor Models in Neuroendocrine Neoplasm
NCT04927611CI-TRIAL-00054060unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to use single-cell sequencing technology to explore neuroendocrine neoplasm (NEN) molecular biological characteristics, tumor heterogeneity and cell subtypes. Besides. NEN models are constructed for basic research, including primary cell lines, organoids, and animal models.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Neoplasm | Neuroendocrine Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy, open or laparoscopic surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Gastroenteropancreatic neuroendocrine neoplasms
- description
- Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
- interventionNames
- Procedure: Biopsy, open or laparoscopic surgery
- label
- Pancreatic ductal adenocarcinoma
- description
- Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
- interventionNames
- Procedure: Biopsy, open or laparoscopic surgery
Primary outcomes (2)
- measure
- Bioinformatics analysis of single-cell sequencing results
- timeFrame
- Half a year
- description
- Analysis of NEN Molecular Biology Information Using Single Cell Sequencing Technology
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Between the ages of 18 and 80, with any gender; 2. Physical fitness score ECOG 0～1 points; 3. The diagnosis is considered as gastrointestinal pancreatic neuroendocrine tumor or pancreatic ductal adenocarcinoma; 4. There is no obvious contraindication to surgery or biopsy; 5. Uncompensated liver cirrhosis, acute and chronic hepatitis and other diseases; 6. No history of other biliary tract related diseases; 7. Volunteer to participate and sign the informed consent form. - Exclusion Criteria: 1. Patients with non-gastrointestinal pancreatic neuroendocrine tumors or pancreatic ductal adenocarcinoma confirmed pathologically; 2. Suffer from other digestive system diseases, such as irritable bowel syndrome, inflammatory bowel disease; 3. Those who have incomplete follow-up data or refuse to accept follow-up; 4. Patients with other malignant tumors or hematological diseases; -
References
Publications (21)
- BACKGROUNDYao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. PMID 18565894
- BACKGROUNDModlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005 May;128(6):1717-51. doi: 10.1053/j.gastro.2005.03.038. PMID 15887161
- BACKGROUNDDasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID 28448665
- BACKGROUNDHallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13. PMID 25312765
- BACKGROUNDModlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. PMID 18177818
- BACKGROUNDSaxena A, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011 Feb;149(2):209-20. doi: 10.1016/j.surg.2010.06.008. Epub 2010 Aug 2. PMID 20674950
- BACKGROUNDPape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008 Dec;15(4):1083-97. doi: 10.1677/ERC-08-0017. Epub 2008 Jul 4.